<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109403</url>
  </required_header>
  <id_info>
    <org_study_id>AGOTRIG</org_study_id>
    <nct_id>NCT05109403</nct_id>
  </id_info>
  <brief_title>Ovarian Response in Oocyte Donors Triggered With GnRH Agonists</brief_title>
  <official_title>Comparison of Ovarian Response in Oocyte Donors Triggered With GnRH Agonists Depending on the LH Level the Day After the Triggering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clínica EUGIN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clínica EUGIN</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of agonist of GnRH (aGnRH) trigger to avoid ovarian hyperstimulation syndrome is&#xD;
      nowadays widely used. The action of the aGnRH in the hypophysis triggers an LH and FSH surge,&#xD;
      which mimicks the natural surge that occurs in the middle of a natural cycle, and thus being&#xD;
      able to elicit the ovulation. However, in some patients the aGnRH trigger ends in a poor&#xD;
      oocyte recuperation, and that has led some physicians to measure the LH surge after the aGnRH&#xD;
      trigger to check its effectiveness.&#xD;
&#xD;
      Even though there is still some discrepancy about the exact cut-off value for a proper LH&#xD;
      surge 12h after the aGnRH trigger, most of the published papers report the value of 15UI/L as&#xD;
      an adequate threshold under which the results of the pick-up are suboptimal. Other authors&#xD;
      even report a value of 52UI/L to predict a decrease in oocyte retrieval and maturity rate and&#xD;
      a value of 15UI/L to predict a dramatic decrease in the results.&#xD;
&#xD;
      Some of the abovementioned studies report that the basal LH value or the LH value on the day&#xD;
      of the trigger could also be predictive of suboptimal responses. Additionally, some authors&#xD;
      have tried to &quot;rescue&quot; the suboptimal patients with a retrigger of hCG, or they have compared&#xD;
      those suboptimal responders with patients triggered with both aGnRH and low doses of hCG. In&#xD;
      both cases the addition of hCG seems to improve the results.&#xD;
&#xD;
      Most of the scientific bibliography available so far is based on infertile patients&#xD;
      undergoing IVF treatments, while in some papers both IVF patients and egg donors have been&#xD;
      analyzed. The current study involves exclusively oocyte donation cycles, where the final aim&#xD;
      is to identify donors at a high risk of a suboptimal response, and to potentially improve&#xD;
      results by potentially adding low doses of hCG (1000 UI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oocyte retrieval rate</measure>
    <time_frame>30 days</time_frame>
    <description>Number of cumulus oocyte complexes (COCs) retrieved divided by the number of follicles &gt; 14mm the day of the last follicular control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oocyte maturity rate</measure>
    <time_frame>30 days</time_frame>
    <description>Number of metaphase-II mature oocytes retrieved divided by the number of COCs retrieved</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Poor Response to Ovulation Induction</condition>
  <arm_group>
    <arm_group_label>LH post-trigger &lt; 15 UI/l</arm_group_label>
    <description>Oocyte donors that present with LH levels &lt; 15UI/I, post trigger by agonists of GnRH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LH post-trigger &gt; 15 UI/l</arm_group_label>
    <description>Oocyte donors that present with LH levels &gt; 15UI/I, post trigger by agonists of GnRH</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Oocyte donors included in the oocyte donation program of Clinica EUGIN&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oocyte donors included in the oocyte donation program of Clinica EUGIN that have been&#xD;
             triggered with GnRH agonists.&#xD;
&#xD;
          -  Any cycle of oocyte donation from the program of Clinica EUGIN, regardless of the type&#xD;
             and dose of gonadotropin used for stimulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Blázquez Ventura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica EUGIN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Blázquez Ventura, MD, PhD</last_name>
    <phone>+34 93 322 11 22</phone>
    <phone_ext>92007</phone_ext>
    <email>ablazquez@eugin.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Miguel Escalada, PhD</last_name>
    <phone>+34 93 322 11 22</phone>
    <phone_ext>92204</phone_ext>
    <email>imiguel@eugin.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica EUGIN</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Blázquez Ventura, MD, PhD</last_name>
      <phone>+34 93 322 11 22</phone>
      <phone_ext>92007</phone_ext>
      <email>ablazquez@eugin.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oocyte donation</keyword>
  <keyword>agonist ovulation trigger</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

